

CORRECTED
VERSION*

CORRECTED
VERSION**

200006348-7



1908

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

International Patent Classification⁷ :
A61K 31/505, C07D 239/70, 487/12

A1

(11) International Publication Number: WO 00/15231

(43) International Publication Date: 28 March 2000 (23.03.00)

International Application Number: PCT/US99/21103

International Filing Date: 15 September 1999 (15.09.99)

Priority Data:

09/154,435 16 September 1998 (16.09.98) US
09/379,300 23 August 1999 (23.08.99) US

Applicant: MEDCO RESEARCH INC. [US/US]; P.O. Box 13886, Research Triangle Park, NC 27709 (US).

Inventors: BARALDI, Pier, Giovanni; Via Fossato di Montara, 17-19, I-44100 Ferrara (IT). BOREA, Pier, Andrea; Via del Turco, 14, I-44100 Ferrara (IT).

Agents: SAVAGE, Michael, G. et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

1) Title: ADENOSINE A₃ RECEPTOR MODULATORS

2) Abstract

The compounds of the formulas described herein wherein R, R¹, R², R³ and A have the meanings given in the specification, are endowed with selective A₃ adenosine receptor agonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A₃ receptor, or can be used in a diagnostic application to determine the relative binding of various compounds to the A₃ receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used *in vivo* or *in vitro* to determine the presence of tumor cells which possess a high concentration of adenosine A₃ receptors.

RECEIVED
9-11-00

RECEIVED

SEP 6 2000

BURNS, DOANE, SWECKER & MATHIS L.L.P.
RESEARCH TRIANGLE PARK, N.C.

618047-118
BURNS, DOANE,
RECEIVED
AUG 31 2000
ENC 9-5-0
SWECKER & MATHIS, L.L.P.

MBS
ARB